In the fight against COVID-19, Indian pharmaceutical companies have made several announcements in recent months on treatments offering hope for patients while investors queued up to buy shares of these companies. However, India-China border dispute escalation may spell trouble for Indian pharma companies. China supplies around two-thirds of Indian pharmaceutical companies’ API needs, with some fermentation-based APIs and vitamins being entirely imported from China. So, how grave is the situation? Mint's Nasrin Sultana speaks to Surajit Pal, pharma analyst, Prabhudas Lilladher about the sector.